중증근무력증의 임상 분류와 척도
Clinical Classification and Scales for Myasthenia Gravis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The variable predominance of the affected muscle groups and the fluctuating severity and extent of myasthenia gravis (MG) makes it difficult to assess and classify these patients. With new treatments being developed and applied, it has become more important to properly classify MG patients and objectively evaluate the results of treatment. So far, a number of clinical classification and assessment systems have been proposed and used individually. However, for the comparative analysis, a uniform set of classifications and reliable measurement methods of muscle impairment are necessary. In this article, MG-clinical classification and several MG-specific assessment tools that are widely used are mentione
Abstract
The variable predominance of the affected muscle groups and the fluctuating severity and extent of myasthenia gravis (MG) makes it difficult to assess and classify these patients. With new treatments being developed and applied, it has become more important to properly classify MG patients and objectively evaluate the results of treatment. So far, a number of clinical classification and assessment systems have been proposed and used individually. However, for the comparative analysis, a uniform set of classifications and reliable measurement methods of muscle impairment are necessary. In this article, MG-clinical classification and several MG-specific assessment tools that are widely used are mentione
참고문헌 (36)
- Gilhus NE, "Myasthenia gravis", N Engl J Med, 375, pp.2570~2581 (2016)
- Osserman KE, "Studies in myasthenia gravis; review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City", AMA Arch Intern Med, 102, pp.72~81 (1958)
- Osserman KE, "Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients", Mt Sinai J Med, 38, pp.497~537 (1971)
- Besinger U, "Long‐term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis", Ann N Y Acad Sci, 377, pp.812~815 (1981)
- Oosterhuis HJ, "Observations of the natural history of myasthenia gravis and the effect of thymectomy", Ann N Y Acad Sci, 377, pp.678~690 (1981)
- Olanow CW, "Thymectomy as primary therapy in myasthenia gravis", Ann N Y Acad Sci, 505, pp.595~606 (1987)
- Jaretzki A 3rd, "“Maximal” thymectomy for myasthenia gravis. Results", J Thorac Cardiovasc Surg, 95, pp.747~757 (1988)
- Barohn R, "New classification system for myasthenia gravis", J Child Neurol, 9, pp.205~ (1994)
- Jaretzki A 3rd, "Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America", Neurology, 55, pp.16~23 (2000)
- Pasnoor M, "A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis", Neurology, 87, pp.57~64 (2016)
- Wolfe GI, "Randomized trial of thymectomy in myasthenia gravis", N Engl J Med, 375, pp.511~522 (2016)
- Howard JF Jr, "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study", Lancet Neurol, 16, pp.976~986 (2017)
- Besinger UA, "Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity", Neurology, 33, pp.1316~1321 (1983)
- Tindall RS, "Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis", N Engl J Med, 316, pp.719~724 (1987)
- Tindall RS, "A clinical therapeutic trial of cyclosporine in myasthenia gravis", Ann N Y Acad Sci, 681, pp.539~551 (1993)
- Barohn RJ, "Reliability testing of the quantitative myasthenia gravis score", Ann N Y Acad Sci, 841, pp.769~772 (1998)
- Meriggioli MN, "Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability", Neurology, 61, pp.1438~1440 (2003)
- Rowin J, "Etanercept treatment in corticosteroid-dependent myasthenia gravis", Neurology, 63, pp.2390~2392 (2004)
- Nagane Y, "Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study", Eur Neurol, 53, pp.146~150 (2005)
- Ponseti JM, "Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study", Clin Neurol Neurosurg, 107, pp.187~190 (2005)
- Wolfe GI, "Myasthenia gravis activities of daily living profile", Neurology, 52, pp.1487~1489 (1999)
- Lee HL, "Physicianand self-assessed myasthenia gravis activities of daily living score", Muscle Nerve, 57, pp.419~422 (2018)
- Muppidi S, "MG-ADL: still a relevant outcome measure", Muscle Nerve, 44, pp.727~731 (2011)
- Wolfe GI, "Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis", Muscle Nerve, 26, pp.549~552 (2002)
- Wolfe GI, "Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy", Ann N Y Acad Sci, 998, pp.473~480 (2003)
- Kawaguchi N, "Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis", Curr Med Res Opin, 20, pp.1269~1273 (2004)
- Takamori M, "Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis", Neurology, 62, pp.1894~1896 (2004)
- Burns TM, "Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite", Muscle Nerve, 38, pp.1553~1562 (2008)
- Burns TM, "The MG composite: a valid and reliable outcome measure for myasthenia gravis", Neurology, 74, pp.1434~1440 (2010)
- Benatar M, "Recommendations for myasthenia gravis clinical trials", Muscle Nerve, 45, pp.909~917 (2012)
- Sanders DB, "A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score", Ann N Y Acad Sci, 998, pp.440~444 (2003)
- Gajdos P, "Long-term effects of plasma exchange in myasthenia. Results of a randomized study", Presse Med, 12, pp.939~942 (1983)
- Raggi A, "Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis", Disabil Rehabil, 36, pp.546~555 (2014)
- Qureshi AI, "Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis", Neurology, 52, pp.629~632 (1999)
- "A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group", J Neurol Neurosurg Psychiatry, 56, pp.1157~1163 (1993)
- 김율희, "Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis", Yonsei Medical Journal, 60(7), pp.633~639 (2019), 연세대학교의과대학[DOI]